Development of a Predictive Tool for Midterm Success of Sacral Neuromodulation in Non‐Neurogenic Overactive Bladder Syndrome
Neurourology and Urodynamics · 2025-06 · 44 (5) · 997-1006
DOI: 10.1002/nau.70041 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Neurourology and Urodynamics, online erschienen am 24.03.2025. Verfasst von Samy Hafez und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Centre Hospitalo-Universitaire de Nantes, Nantes, France. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Electric Stimulation Therapy, Lumbosacral Plexus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Objectives
To identify factors that can predict both test phase and midterm success of sacral neuromodulation (SNM) in refractory non‐neurogenic overactive bladder syndrome (nnOAB) based on preoperative clinical and urodynamic data. Materials and Methods We conducted a two‐center retrospective study and included all individuals with nnOAB who underwent a test phase between 2005 and 2021, with or without subsequent implantation of an SNM device. Only those with preoperative urodynamic assessment data were included. SNM success was defined as 50% improvement in one of the bladder diary parameters, associated with 50% symptom improvement. Individuals underwent follow‐up evaluation at 2 years.
Results
In total, 191 individuals were included (163 women), 69% of whom underwent SNM device implantation. At the preoperative urodynamic exam, 115 individuals had detrusor overactivity (DO). Test phase success was associated with younger age ( p = 0.009). 24‐month SNM success was associated with lower maximal detrusor pressure at DO (Pdet max DO) at baseline ( p = 0.045). Other predictive factors for success at 2 years were female ( p = 0.03), a history of stress incontinence surgery ( p = 0.01), a low maximum urethral closure pressure (MUCP) ( p = 0.04), a low volume at first DO (VFDO) ( p = 0.03), and a high maximum cystometric capacity (MCC) ( p = 0.03). We developed a tool to predict success at 2 years. The following threshold values were significantly associated with treatment success: MUCP < 58 cmH 2 O, VFDO < 170 mL, and MCC > 254 mL.
Conclusion
Age predicted test phase success. Pdet max DO, gender, history of incontinence surgery, high MUCP, MCC, and VFDO predicted midterm success of SNM in people with nnOAB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Centre Hospitalo-Universitaire de Nantes, Nantes, France.
- Centre Hospitalo-Universitaire de Nantes, Direction Recherche Innovation, Plateforme Méthodologie et Biostatistique, Nantes, France.
- Department of Urology, Centre Hospitalo-Universitaire de Lille, Lille, France.
- Inserm UMR-S1172 LilNCog, Lille Neuroscience and Cognition, Université de Lille, Lille, France.
- INSERM, The Enteric Nervous System in Gut and Brain Disorders, Nantes Université, Nantes, France.
Zitieren
APA
Hafez, S., Pere, M., Olivier, L., Carolus, B., De Guerry, M. L., Rigaud, J., Biardeau, X., & Perrouin-Verbe, M. A. (2025). Development of a Predictive Tool for Midterm Success of Sacral Neuromodulation in Non‐Neurogenic Overactive Bladder Syndrome. Neurourology and Urodynamics, 44(5), 997-1006. https://doi.org/10.1002/nau.70041
Vancouver
Hafez S, Pere M, Olivier L, Carolus B, De Guerry ML, Rigaud J, et al. Development of a Predictive Tool for Midterm Success of Sacral Neuromodulation in Non‐Neurogenic Overactive Bladder Syndrome. Neurourology and Urodynamics. 2025;44(5):997-1006. doi:10.1002/nau.70041
BibTeX
@article{Hafez2025,
author = {Hafez, Samy and Pere, Morgane and Olivier, Louise and Carolus, Benjamin and De Guerry, Marie-Liesse and Rigaud, Jérôme and Biardeau, Xavier and Perrouin-Verbe, Marie-Aimée},
title = {Development of a Predictive Tool for Midterm Success of Sacral Neuromodulation in Non‐Neurogenic Overactive Bladder Syndrome},
journal = {Neurourology and Urodynamics},
year = {2025},
volume = {44},
number = {5},
pages = {997--1006},
doi = {10.1002/nau.70041}
}
EUVIMED